The stock price of BriaCell Therapeutics Corp (NASDAQ: BCTX) has dropped by -2.93 compared to previous close of 0.61. Despite this, the company has seen a fall of -45.34% in its stock price over the last five trading days. globenewswire.com reported 2024-12-13 that PHILADELPHIA and VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associated warrant. The warrants have an exercise price of $0.9375 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. Total gross proceeds from the offering, before deducting the underwriter’s discounts and other offering expenses, is $5.55 million.
Is It Worth Investing in BriaCell Therapeutics Corp (NASDAQ: BCTX) Right Now?
The stock has a 36-month beta value of 1.48. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BCTX is 32.47M, and at present, short sellers hold a 2.24% of that float. On December 17, 2024, the average trading volume of BCTX was 2.84M shares.
BCTX’s Market Performance
BCTX stock saw a decrease of -45.34% in the past week, with a monthly decline of -0.79% and a quarterly a decrease of 12.80%. The volatility ratio for the week is 17.25%, and the volatility levels for the last 30 days are 15.33% for BriaCell Therapeutics Corp (BCTX). The simple moving average for the last 20 days is -31.01% for BCTX’s stock, with a simple moving average of -55.21% for the last 200 days.
Analysts’ Opinion of BCTX
Many brokerage firms have already submitted their reports for BCTX stocks, with H.C. Wainwright repeating the rating for BCTX by listing it as a “Buy.” The predicted price for BCTX in the upcoming period, according to H.C. Wainwright is $25 based on the research report published on February 14, 2022 of the previous year 2022.
BCTX Trading at -28.34% from the 50-Day Moving Average
After a stumble in the market that brought BCTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.11% of loss for the given period.
Volatility was left at 15.33%, however, over the last 30 days, the volatility rate increased by 17.25%, as shares surge +1.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.46% lower at present.
During the last 5 trading sessions, BCTX fell by -43.98%, which changed the moving average for the period of 200-days by -82.10% in comparison to the 20-day moving average, which settled at $0.8563. In addition, BriaCell Therapeutics Corp saw -89.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCTX starting from Lustig Marc, who purchase 902,935 shares at the price of $2.21 back on May 14 ’24. After this action, Lustig Marc now owns 2,542,935 shares of BriaCell Therapeutics Corp, valued at $2,000,001 using the latest closing price.
Stock Fundamentals for BCTX
The total capital return value is set at 20.98. Equity return is now at value -202.12, with -29.01 for asset returns.
Currently, EBITDA for the company is -4.77 million with net debt to EBITDA at 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.49.
Conclusion
To sum up, BriaCell Therapeutics Corp (BCTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
